25 May 2013
Keywords: AstraZeneca, fulvestrant, Breast cancer, Research, Licensing partnerships,
Article | 11 December 2009
Data from a new phase III study, presented for the first time yesterday at the annual San Antonio Breast Cancer ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 December 2009
10 December 2009
24 May 2013
© 2013 thepharmaletter.com